Drug Profile
Benzylacyclouridine
Alternative Names: BAU; IND 039655; Uridine phosphorylase inhibitor - PharmaciaLatest Information Update: 24 Sep 2021
Price :
$50
*
At a glance
- Originator Unknown
- Developer Pharmacia Corporation
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 05 Apr 2000 Pharmacia & Upjohn has merged with Monsanto to form Pharmacia Corporation
- 08 Mar 1999 New profile
- 08 Mar 1999 Phase-I clinical trials for Cancer in USA (Unknown route)